Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Kioni Holdings reported a net loss of $116,663 for the nine months ended September 30, 2026, compared to a net profit of $33,674 in the prior year period, primarily due to a significant increase in general and administrative expenses. Despite the year-to-date loss, the company achieved a net profit of $20,343 for the third quarter of 2026 on revenues of $67,722.
Legence Corp. reported record Q3 2026 revenue of $1.31 billion, an 85% increase year-over-year, driven by strong customer demand and the Bowers acquisition. The company also announced that its Board of Directors authorized a new $150 million stock repurchase program and raised its full-year 2026 financial guidance.
Term
Q3 2026
“Strong customer demand drove record third-quarter revenue, Adjusted EBITDA, and backlog and awarded contracts for Legence. Our team continues to deliver exceptional project execution, which along with an increasing mix of fabrication work, contributed to the delivery of the highest Adjusted EBITDA margin in company history.”
ORIX CORP reported a significant decrease in provision for credit losses to ¥1,830 million for the six months ended September 30, 2026, compared to ¥9,781 million in the prior year period. The company utilized fair value options for various assets, including foreign government bonds and loans held for sale, with the latter experiencing a fair value loss of ¥3,152 million in the current period.
CoreWeave reported significant growth for the nine months ended September 30, 2026, with revenue reaching $8.31 billion compared to $3.56 billion in the prior year period. However, the company experienced a substantial increase in operating expenses, particularly in technology and infrastructure, and reported an accumulated deficit of $4.72 billion as of the end of the third quarter.
Twist Bioscience reported record fiscal 2026 revenue of $459.4 million, a 22% increase year-over-year, driven by strong growth in DNA Synthesis and NGS Applications. The company achieved positive adjusted EBITDA in the fourth quarter and improved its annual gross margin to 52.4%. Management issued fiscal 2027 revenue guidance of $550 million to $560 million, representing approximately 21% growth at the midpoint.
Term
FY2026
“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet.”
Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience
“We enter fiscal 2027 with a stronger business and the capital to invest in our next phase of growth. AI is expanding what scientists can design, and personalized medicine is increasing the demand for unique molecules. Both play directly to our strength of customization at scale.”
Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience
AsiaFIN Holdings Corp. reported revenue of $3.96 million for the nine months ended September 30, 2026, a significant increase from $3.20 million in the prior year period. The company achieved a net income of $198,145 for the first nine months of 2026, successfully rebounding from a net loss of $326,764 during the same period in 2025.
flyExclusive, Inc. reported its unaudited financial results for the third quarter ended September 30, 2026. The company filed both a formal press release and a corporate earnings presentation to review its performance and structurally improved business model.
Century Therapeutics reported third quarter 2026 financial results and provided updates on its iPSC-derived cell therapy pipeline. The company remains on track for an IND submission for CNTY-813 in Q4 2026 and expects its CD19-targeted CAR-iT cell therapy, CNTY-308, to enter the clinic by the end of 2026.
“We remain focused on disciplined execution as we rapidly advance our two potentially transformational programs, including CNTY-813, which has the potential to be a functional cure for type 1 diabetes, toward the clinic over the coming months.”
Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics
“With general alignment reached with the FDA for both programs, we remain on track this year for clinical entry of CNTY-308 and IND submission of CNTY-813, positioning us for an important transition to clinical execution in 2027.”
Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics
Pelthos Therapeutics reported total revenue of $41.9 million for the nine months ended September 30, 2026, a significant increase from $7.4 million in the prior year. Despite the revenue growth, the company recorded a net loss of $56.4 million due to high selling, general, and administrative expenses and a $9.3 million loss from the change in fair value of convertible debt.
Generate Biomedicines reported third quarter 2026 financial results, highlighting a cash position of $404.2 million and progress in its Phase 3 asthma studies for GB-0895. The company also noted a significant collaboration with Zealand Pharma in obesity and metabolic diseases with total potential milestones of nearly $1.2 billion.
“Our third quarter results reflect both strong execution across all of our clinical programs and our continued efforts to push the frontiers of programmable biology and therapeutic intelligence. We are making strong progress with GB-0895 in severe asthma, and the data we shared at ERS in COPD further demonstrated the sustained pharmacological activity to support robust modulation of key biomarkers and twice-a-year dosing.”
Mike Nally, chief executive officer of Generate Biomedicines
TScan Therapeutics reports significant ongoing losses and has identified conditions raising substantial doubt about its ability to continue as a going concern. The company is currently non-compliant with Nasdaq's continued listing requirements and requires substantial additional funding to advance its TCR-T therapy product candidates through clinical development.
DPC Holdings reported record Q3 2026 financial results with revenue of $308.1 million, up 39% year-over-year, and a return to GAAP profitability with net income of $31.8 million. The company also announced the acquisition of a 50% stake in Montana Precision Products and a new 10-year strategic customer partnership involving a $200 million capacity investment.
For the nine months ended September 30, 2026, flyExclusive reported revenue of $318.5 million, an increase from $271.6 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $37.8 million, though this was an improvement over the $60.2 million net loss reported for the same period in 2025.
ADI Global Distribution reported Q3 2026 net revenue of $1.31 billion, an 8.6% increase year-over-year, though it recorded a net loss of $655 million due to a significant $659 million non-cash goodwill impairment charge. The impairment was triggered by continued weakness in the residential market and lower projected earnings, leading the company to update its full-year 2026 financial guidance.
SOLV Energy reported record third quarter 2026 financial results with revenue increasing 65% year-over-year to $1.24 billion. The company highlighted a total backlog of approximately $9.2 billion and raised its full-year 2026 financial guidance following the acquisition of ASB Energy Services.
Term
Q3 2026
“SOLV delivered another quarter of strong results, driven by continued execution across the business, our focus on safety, and the dedication of our employees. With a growing backlog, momentum across our operations, and continued demand across our markets, we are raising our full-year guidance and remain focused on disciplined execution, responsible growth, and expanding the value we provide to our customers.”
George Hershman, Chief Executive Officer of SOLV Energy
Absci Corp reported a net loss for the third quarter of 2026 and continues to incur significant losses as it funds its Integrated Drug Creation platform and internal drug programs. As of October 30, 2026, the company had 172,745,810 shares of common stock outstanding and indicated a need for additional capital to fund future operations and clinical development.
Absci Corp reported third quarter 2026 financial results and provided updates on its generative AI-designed therapeutic pipeline. The company is on track to release interim proof-of-concept data for its ABS-201 program in pattern hair loss in December 2026 and plans to initiate a Phase 2 trial for endometriosis in mid-2027.
“As we approach our first look at proof-of-concept data for ABS-201 next month, followed by full data early next year, we are excited for the opportunity to potentially demonstrate our program's ability to stimulate hair regrowth in a convenient and durable way.”
Sean McClain, Founder and CEO
“As ABS-201 progresses through the clinic, we have begun building our commercial infrastructure to support this and potential future programs. In line with that strategy, we are thrilled to be welcoming Gerry Muhle to Absci as our Chief Commercial Officer, whose experience we believe will position ABS-201 and our expanding program pipeline for success.”
Kardigan, Inc. is a clinical-stage biopharmaceutical company focusing on cardiovascular diseases with lead candidates Danicamtiv, Ataciguat, and Tonlamarsen. As of November 2026, the company is an emerging growth company with 93,597,398 shares of common stock outstanding and continues to anticipate significant financial losses as it funds its clinical trials and Prolaio platform development.
Data I/O Corporation reported Q3 2026 revenues of $4.9 million and highlighted the October completion of its $23 million acquisition of V-TEK, Inc. and A&J Programming. The company secured $13.25 million in direct investment and a $7.5 million credit line to fund the transformational deal, which is expected to double revenues and diversify the business into AI, photonics, and robotics markets.
Term
Q3 2026
“The most important measure of our recent performance and our prospects for the future is the completion of the transformational acquisition of V-TEK.”
William Wentworth, President and CEO of Data I/O Corporation
“The NEW Data I/O has become a reality. With the V-TEK acquisition, our expanded products and services now address multibillion-dollar markets. The NEW Data I/O serves industries such as data centers, AI, photonics, industrial automation, robotics, medical, military, aerospace and defense, significantly reducing our reliance on automotive.”
William Wentworth, President and CEO of Data I/O Corporation
Pelthos Therapeutics reported Q3 2026 financial results, highlighted by Zelsuvmi net product revenue of $15.2 million, a 114% increase year-over-year. The company also highlighted its pending transformative merger with Castle Creek Biosciences, which was announced in October 2026 to create a diversified biotechnology company focused on skin diseases.
“Zelsuvmi delivered another solid quarter, generating net product revenue of $15.2 million. Thousands of patients have already benefited from Zelsuvmi and we remain focused on driving Zelsuvmi growth and building on our success with the planned launches of Xepi® targeted in the first quarter of 2027 and Xeglyze® targeted in the third quarter of 2027.”
Scott Plesha, CEO of Pelthos
“In October, after the close of the third quarter, we took an important step in our pursuit of long-term value by announcing our agreement to combine with Castle Creek, a transaction that we believe will create a stronger, more diversified biotechnology company.”
Octave Intelligence reported a significant net loss of $1.86 billion for the nine months ended September 30, 2026, primarily driven by a $2.15 billion 'other operating expense' which includes a substantial goodwill impairment. Despite the bottom-line loss, total revenue grew slightly to $1.20 billion for the nine-month period, supported by a 6% increase in subscription revenue.
BK Technologies reported a net income of $9.67 million for the first nine months of 2026, driven by an 8.3% increase in sales to $69.99 million. The company's cash position strengthened significantly to $29.16 million, despite increased engineering and product development expenses and a $3.0 million investment in a convertible note receivable.
Charlotte’s Web reported Q3 2026 financial results, highlighting its lowest operating loss since 2019 despite a revenue decline. The company attributed the revenue pressure to new full-spectrum hemp restrictions in California and a strategic reduction in deep discounting to improve margins. Management is currently navigating evolving federal hemp policy and negotiating potential pilot programs with healthcare organizations for 2027.
Term
Q3 2026
“Third-quarter revenue primarily reflected the restrictions on the sale of full-spectrum hemp products in California that took effect in July. We have since reintroduced broad-spectrum products in California and sales have steadily begun to recover there. Nationally, we have sharply reduced deep discounting so that our pricing reflects the premium quality and reliable efficacy customers expect from Charlotte’s Web. That lowered revenue in the near term, but it also improved margins and helped deliver our smallest operating loss since 2019.”
Bill Morachnick, Chief Executive Officer of Charlotte’s Web
Applied Aerospace & Defense reported record third-quarter 2026 revenue of $182.1 million, a 48.6% increase year-over-year, driven by strong demand in space and defense end markets. The company generated net income of $30.6 million and grew its contract backlog to nearly $1.3 billion, providing significant multi-year revenue visibility.
Term
Q3 2026
“Our third quarter reflected broad-based demand across our end markets. We delivered record revenue of $182.1 million and Adjusted EBITDA of $39.7 million. Excluding acquisitions completed in 2026, revenue grew 20.3%, while those acquisitions added capabilities and capacity in areas that matter most to our customers.”
Trip Ferguson, Chief Executive Officer of Applied
“What distinguishes Applied is the diversity of our growth. Space and launch systems, defense aviation and airborne systems, and advanced sensing and precision strike systems each delivered double-digit revenue growth, while backlog increased to nearly $1.3 billion across the portfolio.”
Parabilis Medicines reported third-quarter 2026 financial results, ending the period with $1.1 billion in cash and marketable securities. The company reached alignment with the FDA on the Phase 3 registrational trial design for zolucatetide in desmoid tumors, with initiation planned for the first half of 2027. Additionally, the company entered a clinical collaboration with Revolution Medicines to evaluate zolucatetide in combination therapies for metastatic colorectal cancer.
Term
Q3 2026
“With each successive clinical update, we are building a stronger foundation for zolucatetide as a unique medicine with the potential to make a meaningful difference for patients across multiple diseases.”
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President
“The progress across our portfolio continues to strengthen our conviction in the ability of our Helicon platform to repeatedly translate breakthrough science into medicines that can meaningfully improve patients’ lives.”
Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President
Yarrow Bioscience reported third quarter 2026 financial results, ending the period with $268.9 million in cash following a $172.5 million public offering. The company is currently enrolling patients in its Phase 2a/2b DIRECTION-GD trial for YB-101, with topline data expected in the second half of 2027.
“We made significant progress in the third quarter, including dosing our first patient in the Phase 2a portion of the DIRECTION-GD trial and strengthening our balance sheet through the completion of our merger and subsequent public offering. The financing extends our expected cash runway into 2030 and positions us to advance YB-101 in Graves’ disease and prepare for our next steps in thyroid eye disease.”
Rebecca V. Frey, PharmD, President and Chief Executive Officer
Octave Intelligence reported Q3 2026 financial results with total revenue of $415 million and net income of $59 million. The company also announced that its Board of Directors approved a new $200 million share repurchase program, reflecting confidence in its recurring revenue strategy and free cash flow growth.
“Our third quarter results were in line with our expectations, and we remain on track to achieve our outlook for the full year. ARR grew 7% over the prior year to $1.17 billion, and SaaS revenue grew 18%, as we continue our focused shift toward recurring revenue. Product innovation and go-to-market improvements continued to gain traction this quarter, and we’re carrying that momentum into the fourth quarter”
Mattias Stenberg, Chief Executive Officer
“Additionally, our Board of Directors recently approved a $200 million share repurchase program, a decision that reflects its confidence in our company strategy, medium-term financial targets, and ability to grow free cash flow.”
Century Therapeutics reported a total asset increase to $262.6 million as of September 30, 2026, driven by a significant increase in common stock issuance and long-term investments. The company's accumulated deficit grew to $871.6 million, reflecting ongoing development costs for its iPSC-derived immune cell therapies.
Ftai Infrastructure CEO and President Kenneth J. Nicholson Buys $1.53M of Stock
Kenneth J. Nicholson, CEO and President, bought 400,000 shares of Ftai Infrastructure Inc. at $3.83 a share, worth $1.53M in total on Nov 10, 2026. Shares held after the trade: 2,575,539 (+18.4%).
Generate Biomedicines, Inc. is a clinical-stage biotechnology company utilizing its AI-driven 'Generate Platform' for drug discovery. As of October 29, 2026, the company had 129,096,666 shares of common stock outstanding and is classified as an emerging growth company and a non-accelerated filer.